The Role of Dopamine Metabolism in the Antidepressant Effects of Sleep Deprivation and Sertraline in Depressed Patients

University of California, Irvine49 enrolled

Overview

This study evaluates the efficacy of sleep deprivation treatment in accelerating antidepressant responses when administered during the first week of medications and augmenting a sustained response with chronobiological interventions. Sleep deprivation and chronobiological augmentation may offer a rapid and sustained antidepressant response in mood disorder patients treated with medication, sleep deprivation, bright light therapy and sleep phase advance compared with medication only. The chronobiological treatment is rapid, non-invasive and has few side effects and could be of significant clinical benefit.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Major Depressive Disorder Bipolar Disorder

Interventions

sertraline, lithiumDRUG

Antidepressant, Subjects will be started on a serotonin specific reuptake inhibitor (SSRI), sertraline 100 mg (50mg hs x 2) daily or other SSRI's such as Paxil 20 mg or Prozac 20 mg daily and continue treatment for seven weeks. Mood stabilizer, subjects will be treated with lithium 450 mg twice a day or another mood stabilizer such as depakote or valproate and continue treatment for seven weeks.

one night of sleep deprivation and two FDG PET scansRADIATION

MDD Mechanism Only depressed subjects will have two FDG PET scans consisting of a baseline FDG PET scan and a sleep deprived FDG PET scan. One night of regular sleep,one night of sleep deprivation and one night of recovery sleep for a total of four nights at a sleep laboratory facility.

Eligibility

Sex: ALLMin age: 18 YearsMax age: 75 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: Inclusion criteria include: 1. Subjects must be English speaking 2. Subjects must have either bipolar or unipolar depression diagnosis or be a normal control. 3. Subjects must be between : 18 to 75 Non-English speaking subjects will be excluded since scales for measuring depression have not been validated in languages other than English. Exclusion Criteria: Exclusion criteria include: 1. Suicidality, or psychosis 2. Unstable medical conditions 3. Epilepsy, serious head injury, or other significant neurological disorders 4. Dementia, mental retardation (moderate or severe), coma 5. Prior exposure to radiation which might cause the subject to exceed standard guidelines 6. Substance abuse or alcoholism in the past six months 7. Unreliability or inability to adhere to the requirements of the study 8. Irregular sleep-wake schedules (nightshift, jet lag) 9. Use of CNS medications which may affect sleep or functional brain imaging (i.e., use of sleeping pills, antidepressants or other mood stabilizers or other medications which may affect the sleep EEG) 10. Sleep apnea, periodic limb movements of sleep, narcolepsy, circadian sleep phase disorders 11. Donation or loss of blood (\>400 ml) within the past month 12. Current or very recent intercurrent illnesses, painful conditions or other disorders, which in the judgement of the investigators, might invalidate the scientific goals of the study or pose undesirable difficulties or risks for the subject. 13. Hamilton Rating Scale of Depression (HRSD-17 items)\<17 unless subject is a normal control subject. 14. Pregnancy or breast feeding 15. Individuals who would be unable to undergo a magnetic resonance imaging (MRI) scan, for example, individuals who suffer from claustrophobia, or who have metal clips in their body. 16. Unable to cease taking psychoactive medications which are not part of this protocol (2-5 weeks) prior to PET scans. 17. Patients with previous history of significant adverse reactions to sertraline or sertraline-like drugs or other SSRI's such as Paxil or Prozac 18. Subjects with diagnosis of eating disorder/bulimia

Locations (2)

University of California, Irvine

Irvine, California, United States

University of California, San Diego

La Jolla, California, United States

Outcomes

Primary Outcomes

Total Score on the Hamilton Rating Score for Depression (HRSD) - 21 Item Version

Difference in HRSD between the chronobiological augmentation therapy and medication only groups across the first 7 days, and up to 7 weeks of treatment. The 21-item HRSD has a range of 0 to 66, with a higher score indicating more severe depression.

Time frame: within the first seven days up to 7 weeks (plus or minus 1 day) after sleep deprivation and chronobiological therapy